SCHEMBL6153208

SCHEMBL6153208

Cc1ccc(CN2C(=O)C3=C(c4ccc(-c5ccc(C)cc5)c5ccccc45)N(Cc4ccc(C)cc4)C(=O)C3=C2c2ccc(-c3ccc(C)cc3)c3ccccc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RGS4 P49798 1/20 0.47
P2RX4 Q99571 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CA12 O43570 2/20 0.41
CA9 Q16790 2/20 0.41
ALDH1A1 P00352 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
LMNA P02545 2/20 0.40
TP53 P04637 1/20 0.40
MDH2 P40926 1/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2457896 0.85 GSK3B (0.47) P2RX4SMN1; SMN2TDP1CA12CA9
SCHEMBL2457350 0.85 RGS4 (0.41) RGS4P2RX4SMN1; SMN2CA12CA9
SCHEMBL6153269 0.82 GSK3B (0.45) P2RX4SMN1; SMN2TDP1CA12CA9
SCHEMBL10086968 0.81 P2RX4 (0.43) RGS4P2RX4CA12CA9CA1
SCHEMBL6152286 0.79 COMT (0.42) ALDH1A1MEN1KMT2ASIRT2POLB
SCHEMBL7070855 0.74 RGS4 (0.52) RGS4TDP1ALDH1A1MEN1KMT2A
SCHEMBL8737445 0.73 CASP3 (0.65) CA12CA9CA1CA2ADRA1D
SCHEMBL29820192 0.73 CASP3 (0.65) CA12CA9CA1CA2ADRA1D
SCHEMBL1719186 0.73 CYP1B1 (0.50) CA12CA9ALDH1A1CA1MEN1
SCHEMBL12561342 0.73 MAPT (0.53) RGS4SMN1; SMN2TDP1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253151-B1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES (JP) 2005-01-12 EP disclosed
US-6805978-B2 COMPLEX CONTAINING DIKETOPYRROLO(3,4-C)PYRROLE COMPOUND TORAY INDUSTRIES, INC. (JP) 2004-10-19 US disclosed
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound TORAY INDUSTRIES, INC. (JP) 2003-05-01 US disclosed
EP-1253151-A1 Pyrromethene metal complex and light emitting device composition and light emitting devices using the same TORAY INDUSTRIES, INC. (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030082406-A1 Complex containing diketopyrrolo(3,4-c)pyrrole compound PPOX, CPNE4, TP53RK RGS4 2393/4885P2RX4 118/4885SMN1; SMN2 4804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.